Tibial cortex transverse transport regulates Orai1/STIM1-mediated NO release and improve the migration and proliferation of vessels via increasing osteopontin expression

Kong, Lingchao; Li, Yangyang; Deng, Zhongfang; Chen, Xiaoyu; Xia, Yin; Shen, Bing; Ning, Rende; Zhang, Lesha; Yin, Zongsheng

doi:10.1016/j.jot.2024.02.007

Cited by 3 publications

(1 citation statement)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After distraction osteogenesis, the blood vessel volume density in the distracted callus and in the surrounding soft tissues on the movement side of the limb was increased, indicating distraction osteogenesis activated angiogenesis and maintained increasing vascularity [ 24 ]. An experimental study of TTT in rats also found the migration, proliferation, and angiogenesis of human umbilical vein endothelial cells were improved after TTT and thus the wound was ultimately accelerated [ 25 ]. El-Alfy et al believed that distraction osteogenesis machinery could healed the soft tissue defects during the process of bone transport [ 26 ].…”

Section: Discussionmentioning

confidence: 99%

Efficacy of tibial cortex transverse transport in treating diabetic foot ulcer and its effect on serum omentin-1 and irisin levels

Wen,

Chen,

Lan

et al. 2024

Diabetol Metab Syndr

View full text Add to dashboard Cite

Objective Diabetic foot ulcer (DFU) is a common and debilitating complication of diabetes that is associated with an increased risk of lower-limb amputation and a reduced life expectancy. Tibial cortex transverse transport (TTT) has become a newly alternative surgical method to facilitate ulcer healing and prevent lower limb amputation. Herein, we investigated the efficacy of TTT in treating DFU and changes of serum omentin-1 and irisin levels. Methods This study prospectively recruited 52 consecutive patients with DFU who were treated with TTT. The follow-up was performed weekly during the first 12 weeks postoperatively and every 3 months until 1 year after TTT. The serum levels of vascular endothelial growth factor (VEGF), omentin-1, and irisin in DFU patients undergoing TTT were determined by ELISA methods on the preoperative 1st day, postoperative 2nd week and 4th week. Results The wound healing rate was 92.3% (48/52) at the 1-year follow-up. The visual analog scale (VAS) pain scores of patients showed a significant reduction at the 4th week after TTT (p < 0.001). The dorsal foot skin temperature, ankle brachial index, and dorsal foot blood flow of patients were significantly increased at the 4th week after TTT (p < 0.001). Results of ELISA methods showed the serum levels of VEGF, omentin-1, and irisin on the 2nd week and 4th week after TTT were notably elevated compared to the levels determined on the preoperative 1st day (p < 0.001). The serum levels of VEGF, omentin-1, and irisin on the 4th week after TTT were also significantly higher than the levels determined on the 2nd week after TTT (p < 0.001). Conclusion TTT could promote the wound healing and reduce the risk of lower limb amputation, demonstrating promising clinical benefits in the treatment of DFU. Increased expressions of serum proangiogenic factors including VEGF, omentin-1, and irisin were noted in the early stage after TTT, which may provide a new mechanism of TTT promoting wound heal.

show abstract

Section: Discussionmentioning

confidence: 99%

Efficacy of tibial cortex transverse transport in treating diabetic foot ulcer and its effect on serum omentin-1 and irisin levels

Wen,

Chen,

Lan

et al. 2024

Diabetol Metab Syndr

View full text Add to dashboard Cite

show abstract

Basic research is the foundation and driving force for clinical translation

2024

Journal of Orthopaedic Translation

View full text Add to dashboard Cite

Neural repair function of osteopontin in stroke and stroke‑related diseases (Review)

Sun,

2024

Exp Ther Med

View full text Add to dashboard Cite

Stroke, including hemorrhagic stroke and ischemic stroke, is a common disease of the central nervous system. It is characterized by a high mortality and disability rate and is closely associated with atherosclerosis, hypertension hyperglycemia, atrial fibrillation and unhealthy living habits. The continuous development of surgery and medications has decreased the mortality rate of patients with stroke and has greatly improved the disease prognosis. At present, the direction of clinical treatment and research has gradually shifted to the repair of nerve function after stroke. Osteopontin (OPN) is a widely distributed extracellular matrix protein. Due to its structural characteristics, OPN can be cut and modified into terminal fragments with different functions, which play different roles in various pathophysiological processes, such as formation of tumors, inflammation and autoimmune diseases. It has also become a potential diagnostic and therapeutic marker. In order to comprehensively analyze the specific role of OPN in nerve repair and its relationship with stroke and stroke-related diseases, the following key words were used: ‘Osteopontin, stroke, atherosis, neuroplasticity, neural repair’. PubMed, Web of Science and Cochrane articles related to OPN were searched and summarized. The present review describes the OPN structure, isoforms, functions and its neural repair mechanism, and its association with the occurrence and development of stroke and related diseases was explored.

show abstract

Tibial cortex transverse transport regulates Orai1/STIM1-mediated NO release and improve the migration and proliferation of vessels via increasing osteopontin expression

Cited by 3 publications

References 41 publications

Efficacy of tibial cortex transverse transport in treating diabetic foot ulcer and its effect on serum omentin-1 and irisin levels

Efficacy of tibial cortex transverse transport in treating diabetic foot ulcer and its effect on serum omentin-1 and irisin levels

Basic research is the foundation and driving force for clinical translation

Neural repair function of osteopontin in stroke and stroke‑related diseases (Review)

Contact Info

Product

Resources

About